Publicaciones en colaboración con investigadores/as de KU Leuven (4)

2022

  1. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

    Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520

2021

  1. Empagliflozin in heart failure with a preserved ejection fraction

    New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461

  2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

2020

  1. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

    European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392